Ozempic maker Novo Nordisk nudges higher profit forecast

• Novo Nordisk shares jump 8% after Wegovy sales beat expectations

  Business - CNBC - November 6

• The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

  Top stories - CBS News - November 4

• Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies

  Business - CNBC - October 23
• 

  Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats

  Politics - The Hill - October 23

• Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

  Business - CNBC - October 24

• Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says

  Business - CNBC - October 30

• With Novo Nordisk success, is there a "Nokia risk" for Denmark?

  Top stories - CBS News - November 3
• 

  Novo Nordisk's Wegovy Sales Beat Expectations

  Business - The Wall Street Journal - November 6

More from MarketWatch

• Analysts don’t budge on Williams-Sonoma ratings despite stock rally

  Business - MarketWatch - 8 minutes ago

• Is higher inflation here to stay? Fed faces hurdles in quest to crush rising prices.

  Business - MarketWatch - 17 minutes ago

• Treasury yields steady as traders weigh increased Russia-Ukraine tensions

  Business - MarketWatch - 18 minutes ago

• Philadelphia Fed’s manufacturing gauge shows activity contracted in November

  Business - MarketWatch - 24 minutes ago

• MicroStrategy’s stock could do something it hasn’t done in 24 years as bitcoin surges

  Business - MarketWatch - 37 minutes ago